Arbutus Biopharma announced a significant leadership transition, appointing Lindsay Androski, J.D., M.B.A., as its new Chief Executive Officer, effective immediately. Ms. Androski replaces Michael J. McElhaugh, who served as Interim President and CEO.
Concurrently, the company underwent a complete overhaul of its Board of Directors. Four new directors—Robert Alan Beardsley, Joseph Bishop, Matthew Gline, and Anuj Hasija—joined the board, while all existing members stepped down, reducing the board to five members.
The new leadership team will temporarily pause participation in investor meetings and conferences to review development plans and strategic options for its hepatitis B programs. This indicates a period of strategic re-evaluation under the new management.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.